Belite Bio reported positive top‑line results from its Phase III DRAGON trial: oral tinlarebant produced a statistically significant reduction in retinal lesion growth versus placebo in Stargardt disease type 1. The company said the study met its primary endpoint with a clinically meaningful slowing of lesion progression, positioning tinlarebant as the first potential disease‑modifying oral therapy for STGD1. Belite’s announcement was followed by a rapid market response and immediate plans to pursue regulatory filing discussions. Clinical investigators noted the mechanism—lowering serum retinol binding protein 4—targets a driver of retinal toxic retinoid accumulation. If regulators agree on the clinical meaningfulness of the imaging endpoint, Belite could move quickly toward submission and commercialization. The result is notable both for rare‑disease therapeutic development and for investors watching late‑stage readouts after years of negative trials in inherited retinal disorders.